Temozolomide Resistance in Glioblastoma Multiforme

Overview

Journal Genes Dis

Date 2018 Sep 28

PMID 30258889

Citations 503

Authors

Sang Y Lee

Affiliations

Soon will be listed here.

Abstract

Temozolomide (TMZ) is an oral alkylating agent used to treat glioblastoma multiforme (GBM) and astrocytomas. However, at least 50% of TMZ treated patients do not respond to TMZ. This is due primarily to the over-expression of O-methylguanine methyltransferase (MGMT) and/or lack of a DNA repair pathway in GBM cells. Multiple GBM cell lines are known to contain TMZ resistant cells and several acquired TMZ resistant GBM cell lines have been developed for use in experiments designed to define the mechanism of TMZ resistance and the testing of potential therapeutics. However, the characteristics of intrinsic and adaptive TMZ resistant GBM cells have not been systemically compared. This article reviews the characteristics and mechanisms of TMZ resistance in natural and adapted TMZ resistant GBM cell lines. It also summarizes potential treatment options for TMZ resistant GBMs.

Citing Articles

Eribulin exerts multitarget antineoplastic activity in glioma cells.

Alcantara G, do Nascimento M, de Miranda L, de Almeida B, Lima K, Rego E Pharmacol Rep. 2025; .

PMID: 40056292 DOI: 10.1007/s43440-025-00711-y.

Exploratory Study on Nanoparticle Co-Delivery of Temozolomide and Ligustilide for Enhanced Brain Tumor Therapy.

Ke G, Zhang M, Hu P, Zhang J, Naeem A, Wang L Pharmaceutics. 2025; 17(2).

PMID: 40006558 PMC: 11858958. DOI: 10.3390/pharmaceutics17020191.

GRP78 in Glioma Progression and Therapy: Implications for Targeted Approaches.

Yang Y, Li W, Zhao Y, Sun M, Xing F, Yang J Biomedicines. 2025; 13(2).

PMID: 40002794 PMC: 11852679. DOI: 10.3390/biomedicines13020382.

MR‑guided laser interstitial thermal therapy followed by early application of temozolomide for recurrent IDH-wildtype glioblastomas: preliminary results from a prospective study.

Zhao X, Li C, Wang K, Zhang Y, Wan H, Yang P Neurosurg Rev. 2025; 48(1):254.

PMID: 39971799 DOI: 10.1007/s10143-025-03402-7.

Metformin and glioma: Targeting metabolic dysregulation for enhanced therapeutic outcomes.

Basheer H, Salman N, Abdullah R, Elsalem L, Afarinkia K Transl Oncol. 2025; 53:102323.

PMID: 39970627 PMC: 11876755. DOI: 10.1016/j.tranon.2025.102323.

References

Hermisson M, Klumpp A, Wick W, Wischhusen J, Nagel G, Roos W . O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J Neurochem. 2006; 96(3):766-76. DOI: 10.1111/j.1471-4159.2005.03583.x. View

McFaline-Figueroa J, Braun C, Stanciu M, Nagel Z, Mazzucato P, Sangaraju D . Minor Changes in Expression of the Mismatch Repair Protein MSH2 Exert a Major Impact on Glioblastoma Response to Temozolomide. Cancer Res. 2015; 75(15):3127-38. PMC: 4526337. DOI: 10.1158/0008-5472.CAN-14-3616. View

Banelli B, Carra E, Barbieri F, Wurth R, Parodi F, Pattarozzi A . The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma. Cell Cycle. 2015; 14(21):3418-29. PMC: 4825557. DOI: 10.1080/15384101.2015.1090063. View

Kitange G, Carlson B, Schroeder M, Grogan P, Lamont J, Decker P . Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. Neuro Oncol. 2008; 11(3):281-91. PMC: 2718972. DOI: 10.1215/15228517-2008-090. View

Quinn J, Jiang S, Reardon D, Desjardins A, Vredenburgh J, Rich J . Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol. 2009; 27(8):1262-7. PMC: 2667825. DOI: 10.1200/JCO.2008.18.8417. View

Hegi M, Liu L, Herman J, Stupp R, Wick W, Weller M . Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol. 2008; 26(25):4189-99. DOI: 10.1200/JCO.2007.11.5964. View

Munoz J, Rodriguez-Cruz V, Greco S, Ramkissoon S, Ligon K, Rameshwar P . Temozolomide resistance in glioblastoma cells occurs partly through epidermal growth factor receptor-mediated induction of connexin 43. Cell Death Dis. 2014; 5:e1145. PMC: 3973225. DOI: 10.1038/cddis.2014.111. View

St-Coeur P, Poitras J, Cuperlovic-Culf M, Touaibia M, Morin Jr P . Investigating a signature of temozolomide resistance in GBM cell lines using metabolomics. J Neurooncol. 2015; 125(1):91-102. DOI: 10.1007/s11060-015-1899-6. View

Ueno H, Tomiyama A, Yamaguchi H, Uekita T, Shirakihara T, Nakashima K . Augmentation of invadopodia formation in temozolomide-resistant or adopted glioma is regulated by c-Jun terminal kinase-paxillin axis. Biochem Biophys Res Commun. 2015; 468(1-2):240-7. DOI: 10.1016/j.bbrc.2015.10.122. View

10.

Auger N, Thillet J, Wanherdrick K, Idbaih A, Legrier M, Dutrillaux B . Genetic alterations associated with acquired temozolomide resistance in SNB-19, a human glioma cell line. Mol Cancer Ther. 2006; 5(9):2182-92. DOI: 10.1158/1535-7163.MCT-05-0428. View

11.

Quirt I, Verma S, Petrella T, Bak K, Charette M . Temozolomide for the treatment of metastatic melanoma: a systematic review. Oncologist. 2007; 12(9):1114-23. DOI: 10.1634/theoncologist.12-9-1114. View

12.

Bredel M, Bredel C, Juric D, Duran G, Yu R, Harsh G . Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappaB-mediated resistance to O6-alkylating agents in human glioblastomas. J Clin Oncol. 2005; 24(2):274-87. DOI: 10.1200/JCO.2005.02.9405. View

13.

Giannini C, Sarkaria J, Saito A, Uhm J, Galanis E, Carlson B . Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro Oncol. 2005; 7(2):164-76. PMC: 1871885. DOI: 10.1215/S1152851704000821. View

14.

Kanzawa T, Bedwell J, Kondo Y, Kondo S, Germano I . Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide. J Neurosurg. 2004; 99(6):1047-52. DOI: 10.3171/jns.2003.99.6.1047. View

15.

Nguyen S, Stechishin O, Luchman H, Lun X, Senger D, Robbins S . Novel MSH6 mutations in treatment-naïve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation. Clin Cancer Res. 2014; 20(18):4894-903. DOI: 10.1158/1078-0432.CCR-13-1856. View

16.

Chong D, Toh X, Ho I, Sia K, Newman J, Yulyana Y . Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status. BMC Cancer. 2015; 15:255. PMC: 4408574. DOI: 10.1186/s12885-015-1191-3. View

17.

Uno M, Oba-Shinjo S, Camargo A, Moura R, Aguiar P, Cabrera H . Correlation of MGMT promoter methylation status with gene and protein expression levels in glioblastoma. Clinics (Sao Paulo). 2011; 66(10):1747-55. PMC: 3180167. DOI: 10.1590/s1807-59322011001000013. View

18.

Montaldi A, Godoy P, Sakamoto-Hojo E . APE1/REF-1 down-regulation enhances the cytotoxic effects of temozolomide in a resistant glioblastoma cell line. Mutat Res Genet Toxicol Environ Mutagen. 2015; 793:19-29. DOI: 10.1016/j.mrgentox.2015.06.001. View

19.

Newlands E, Blackledge G, Slack J, Rustin G, Smith D, Stuart N . Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer. 1992; 65(2):287-91. PMC: 1977719. DOI: 10.1038/bjc.1992.57. View

20.

Moody C, Wheelhouse R . The medicinal chemistry of imidazotetrazine prodrugs. Pharmaceuticals (Basel). 2014; 7(7):797-838. PMC: 4113733. DOI: 10.3390/ph7070797. View